Global Neutropenia Biologic Drug Treatment Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Market Analysis by Type
  • 1.3.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type: 2020 VS 2026
  • 1.3.2 Filgrastim
  • 1.3.3 Pegfilgrastim
  • 1.3.4 Lenograstim
  • 1.3.5 Lipegfilgrastim
  • 1.3.6 Sargramostim
• 1.4 Market by Application
  • 1.4.1 Global Neutropenia Biologic Drug Treatment Market Share by Application: 2020 VS 2026
  • 1.4.2 Retail Pharmacies
  • 1.4.3 Hospital Pharmacies
  • 1.4.4 Online Pharmacies
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2015-2026)
• 2.2 Neutropenia Biologic Drug Treatment Growth Trends by Regions
  • 2.2.1 Neutropenia Biologic Drug Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neutropenia Biologic Drug Treatment Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neutropenia Biologic Drug Treatment Forecasted Market Size by Regions (2021-2026)
• 2.3 Neutropenia Biologic Drug Treatment Industry Dynamic
  • 2.3.1 Neutropenia Biologic Drug Treatment Market Trends
  • 2.3.2 Neutropenia Biologic Drug Treatment Market Drivers
  • 2.3.3 Neutropenia Biologic Drug Treatment Market Challenges
  • 2.3.4 Neutropenia Biologic Drug Treatment Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Neutropenia Biologic Drug Treatment Players by Market Size
  • 3.1.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue (2015-2020)
  • 3.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2015-2020)
• 3.2 Global Neutropenia Biologic Drug Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Neutropenia Biologic Drug Treatment Revenue
• 3.4 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio
  • 3.4.1 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Neutropenia Biologic Drug Treatment Revenue in 2019
• 3.5 Key Players Neutropenia Biologic Drug Treatment Area Served
• 3.6 Key Players Neutropenia Biologic Drug Treatment Product Solution and Service
• 3.7 Date of Enter into Neutropenia Biologic Drug Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Neutropenia Biologic Drug Treatment Breakdown Data by Type

• 4.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Type (2015-2020)
• 4.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2021-2026)

5 Neutropenia Biologic Drug Treatment Breakdown Data by Application

• 5.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Application (2015-2020)
• 5.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neutropenia Biologic Drug Treatment Market Size (2015-2026)
• 6.2 North America Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
• 6.3 North America Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
• 6.4 North America Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Neutropenia Biologic Drug Treatment Market Size (2015-2026)
• 7.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
• 7.3 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
• 7.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size (2015-2026)
• 8.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
• 8.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
• 8.4 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia

9 Latin America

• 9.1 Latin America Neutropenia Biologic Drug Treatment Market Size (2015-2026)
• 9.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
• 9.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
• 9.4 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2015-2026)
• 10.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2015-2020)
• 10.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2015-2020)
• 10.4 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE

11Key Players Profiles

• 11.1 Teva Pharmaceutical
  • 11.1.1 Teva Pharmaceutical Company Details
  • 11.1.2 Teva Pharmaceutical Business Overview
  • 11.1.3 Teva Pharmaceutical Neutropenia Biologic Drug Treatment Introduction
  • 11.1.4 Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020))
  • 11.1.5 Teva Pharmaceutical Recent Development
• 11.2 Amgen
  • 11.2.1 Amgen Company Details
  • 11.2.2 Amgen Business Overview
  • 11.2.3 Amgen Neutropenia Biologic Drug Treatment Introduction
  • 11.2.4 Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.2.5 Amgen Recent Development
• 11.3 Sanofi
  • 11.3.1 Sanofi Company Details
  • 11.3.2 Sanofi Business Overview
  • 11.3.3 Sanofi Neutropenia Biologic Drug Treatment Introduction
  • 11.3.4 Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.3.5 Sanofi Recent Development
• 11.4 Mylan(Fulphila)
  • 11.4.1 Mylan(Fulphila) Company Details
  • 11.4.2 Mylan(Fulphila) Business Overview
  • 11.4.3 Mylan(Fulphila) Neutropenia Biologic Drug Treatment Introduction
  • 11.4.4 Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.4.5 Mylan(Fulphila) Recent Development
• 11.5 Kyowa Kirin
  • 11.5.1 Kyowa Kirin Company Details
  • 11.5.2 Kyowa Kirin Business Overview
  • 11.5.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Introduction
  • 11.5.4 Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.5.5 Kyowa Kirin Recent Development
• 11.6 Novartis
  • 11.6.1 Novartis Company Details
  • 11.6.2 Novartis Business Overview
  • 11.6.3 Novartis Neutropenia Biologic Drug Treatment Introduction
  • 11.6.4 Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.6.5 Novartis Recent Development
• 11.7 Spectrum Pharmaceuticals
  • 11.7.1 Spectrum Pharmaceuticals Company Details
  • 11.7.2 Spectrum Pharmaceuticals Business Overview
  • 11.7.3 Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
  • 11.7.4 Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.7.5 Spectrum Pharmaceuticals Recent Development
• 11.8 Pfizer
  • 11.8.1 Pfizer Company Details
  • 11.8.2 Pfizer Business Overview
  • 11.8.3 Pfizer Neutropenia Biologic Drug Treatment Introduction
  • 11.8.4 Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.8.5 Pfizer Recent Development
• 11.9 Baxter International
  • 11.9.1 Baxter International Company Details
  • 11.9.2 Baxter International Business Overview
  • 11.9.3 Baxter International Neutropenia Biologic Drug Treatment Introduction
  • 11.9.4 Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.9.5 Baxter International Recent Development
• 11.10 Partner Therapeutics(Leukine)
  • 11.10.1 Partner Therapeutics(Leukine) Company Details
  • 11.10.2 Partner Therapeutics(Leukine) Business Overview
  • 11.10.3 Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Introduction
  • 11.10.4 Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 11.10.5 Partner Therapeutics(Leukine) Recent Development
• 11.11 BeyondSpring Pharmaceuticals
  • 10.11.1 BeyondSpring Pharmaceuticals Company Details
  • 10.11.2 BeyondSpring Pharmaceuticals Business Overview
  • 10.11.3 BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
  • 10.11.4 BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 10.11.5 BeyondSpring Pharmaceuticals Recent Development
• 11.12 Cellerant Therapeutics
  • 10.12.1 Cellerant Therapeutics Company Details
  • 10.12.2 Cellerant Therapeutics Business Overview
  • 10.12.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Introduction
  • 10.12.4 Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 10.12.5 Cellerant Therapeutics Recent Development
• 11.13 Enzychem Lifesciences Corporation
  • 10.13.1 Enzychem Lifesciences Corporation Company Details
  • 10.13.2 Enzychem Lifesciences Corporation Business Overview
  • 10.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Introduction
  • 10.13.4 Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 10.13.5 Enzychem Lifesciences Corporation Recent Development
• 11.14 Myelo Therapeutics
  • 10.14.1 Myelo Therapeutics Company Details
  • 10.14.2 Myelo Therapeutics Business Overview
  • 10.14.3 Myelo Therapeutics Neutropenia Biologic Drug Treatment Introduction
  • 10.14.4 Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 10.14.5 Myelo Therapeutics Recent Development
• 11.15 Generon
  • 10.15.1 Generon Company Details
  • 10.15.2 Generon Business Overview
  • 10.15.3 Generon Neutropenia Biologic Drug Treatment Introduction
  • 10.15.4 Generon Revenue in Neutropenia Biologic Drug Treatment Business (2015-2020)
  • 10.15.5 Generon Recent Development

12Analyst's Viewpoints/Conclusions

13Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer